Literature DB >> 8888346

Newer treatments for inflammatory bowel disease.

B R Stotland1, G R Lichtenstein.   

Abstract

Despite intense investigative efforts, the causes of ulcerative colitis and Crohn's disease remain elusive. The mainstay of medical therapy focuses on inhibition of the effects of the inflammatory mediators operant in inflammatory bowel disease because the causes of these two chronic disorders are unknown. During recent years, the physician's armamentarium for medical treatment of inflammatory bowel disease has increased substantially. In this article, the current standard medical therapies available for treatment of patients with inflammatory bowel disease are reviewed along with their efficacy; the side effects and status of other investigative drugs also are reviewed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8888346     DOI: 10.1016/s0095-4543(05)70349-3

Source DB:  PubMed          Journal:  Prim Care        ISSN: 0095-4543            Impact factor:   2.907


  3 in total

1.  Refractory Inflammatory Bowel Disease.

Authors:  Thomas A. Judge; Gary R. Lichtenstein
Journal:  Curr Treat Options Gastroenterol       Date:  2001-06

2.  Anti-inflammatory drugs and endothelial cell adhesion molecule expression in murine vascular beds.

Authors:  N Mori; Y Horie; M E Gerritsen; D C Anderson; D N Granger
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

Review 3.  Comparative tolerability of treatments for inflammatory bowel disease.

Authors:  R B Stein; S B Hanauer
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.